---
title: "Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Indication questions"
description: "Indication questions on Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Vabysmo approved for wet AMD? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Indication questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

Indication questions that apply to every indication of Vabysmo are on [Vabysmo (faricimab-svoa), all indications: Indication](https://www.evicenter.com/medical-information/vabysmo/indication).

## Indication

<a id="vabysmo-namd-indication"></a>

### Is Vabysmo approved for wet AMD?

> “VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor 
> indicated for the treatment of patients with: 
>
> 1.1 
> Neovascular (wet) Age-Related Macular Degeneration (nAMD)”

Source: [VABYSMO: Prescribing information, page 2, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=2)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)
- [Clinical trials](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration)
